This analysis demonstrates the effectiveness of methotrexate application via microinfusion in frontal fibrosing alopecia.

Stryker’s OptaBlate, the company’s first basivertebral nerve ablation system earned FDA 510(k) clearance. OptaBlate is used for a minimally invasive, target procedure for chronic vertebrogenic low back pain, according to a May 19 news release. It achieves at least a 1 centimeter lesion in seven minutes, is steerable and has microinfusion technology to improve precision. […]

According to a new study,Methotrexate microinfusion (MMP) is a well-tolerated and effective treatment for frontal fibrosing alopecia (FFA), significantly reducing symptoms and halting disease...

Stryker (NYSE:SYK) has received FDA 510(k) clearance for its OptaBlate basivertebral nerve ablation system (OptaBlate BVN), designed to treat chronic vertebrogenic low back pain. The system represents a minimally invasive solution that targets the basivertebral nerve for long-lasting pain relief. Key features include achieving a 1 cm lesion in 7 minutes, steerable curved introducer, microinfusion technology for hydration, and 10-gauge access tools. This addition expands Stryker's pain management portfolio, combining their expertise in radiofrequency ablation technology and vertebral access. The system will be showcased at the American Society of Pain & Neuroscience Annual Meeting in Miami, FL, July 17-20.